EURASIAN JOURNAL OF MEDICAL AND
NATURAL SCIENCES
Innovative Academy Research Support Center
IF = 7.921
Volume 5 Issue 8, August 2025 ISSN 2181-287X
Page 28
ARTIFICIAL INTELLIGENCE IN PHARMACY:
APPLICATIONS, CHALLENGES, AND FUTURE
PERSPECTIVES
Raxmonov E.D.
Head of the Center for Digital Educational Technologies of the Tashkent
Pharmaceutical Institute, Tashkent, Republic of Uzbekistan, Mirabad
district, Oybek 45,
e-mail: erkinrakhmanov@gmail.com
Orcid:0009-0009-9677-6762
https://doi.org/10.5281/zenodo.16777502
ARTICLE INFO
ABSTRACT
Received: 01
st
August 2025
Accepted: 06
th
August 2025
Online: 07
th
August 2025
This comprehensive review examines the multifaceted
applications of Artificial Intelligence (AI) across the
pharmaceutical industry, including drug discovery, clinical
trials, pharmacovigilance, personalized medicine, and
pharmaceutical manufacturing. The article also investigates
the technical, ethical, regulatory, and economic challenges
associated with AI implementation. Future prospects such as
digital twin technologies, quantum computing, and
biologically interfaced AI are discussed. The study includes
systematic analysis of 157 Scopus-indexed publications,
expert assessments, and policy frameworks. The paper
concludes with specific strategic recommendations for
Uzbekistan to establish itself as a regional AI leader in
pharmaceutical innovation.
KEYWORDS
Artificial Intelligence (AI),
pharmaceutical
industry,
drug development, machine
learning,
personalized
medicine,
pharmacovigilance,
regulatory
frameworks,
FDA, EMA.
INTRODUCTION
Artificial Intelligence (AI) is reshaping the pharmaceutical sector by offering new
methods of drug development, enhancing clinical trials, and enabling personalized treatment
approaches. AI's potential to reduce drug development timeframes and costs is substantial.
Between 2019 and 2024, the global pharmaceutical AI market expanded by over 467%,
reflecting a broader shift towards digital transformation. AI technologies, such as machine
learning, deep learning, and natural language processing, have enabled faster discovery of
drug candidates and optimization of trial protocols.
The convergence of big data, genomics, and AI now allows the prediction of molecular
interactions, identification of new therapeutic targets, and even simulation of entire clinical
trials in silico. Organizations such as Exscientia and Insilico Medicine have demonstrated that
AI can compress drug discovery timelines from 5 years to as little as 12–18 months.
AI plays a pivotal role in accelerating the process of drug discovery by utilizing
algorithms that can analyze vast chemical libraries and biological datasets. Generative AI
models, such as generative adversarial networks (GANs), GPT-4, and AlphaFold 2, are used to
predict viable drug candidates and protein structures with high accuracy. For example,
AlphaFold 2 predicted the 3D structures of over 200 million proteins, fundamentally
transforming structural biology.
EURASIAN JOURNAL OF MEDICAL AND
NATURAL SCIENCES
Innovative Academy Research Support Center
IF = 7.921
Volume 5 Issue 8, August 2025 ISSN 2181-287X
Page 29
Companies like Insilico Medicine have used AI to design novel drug candidates for
conditions such as idiopathic pulmonary fibrosis, moving from target identification to
preclinical trials in under two years—a process that typically spans five years.
AI improves patient recruitment, eligibility matching, and monitoring in clinical trials.
Tools like IBM Watson and Deep 6 AI have made significant impacts. Digital twin technologies
allow for the creation of simulated patient populations, which can reduce trial durations by up
to 45%. Moreover, AI-based platforms can predict adverse events and therapy responses in
real-time, optimizing safety and efficacy.
Post-marketing surveillance has been revolutionized by AI systems capable of mining
data from electronic health records, social media, and global reporting systems. For example,
the FDA’s Sentinel System uses AI to monitor over 100 million patient records. Social listening
platforms can detect adverse drug reactions (ADRs) with 85% accuracy by analyzing public
posts and sentiment patterns.
AI enables the development of individualized treatment plans by integrating genomic,
proteomic, and phenotypic data. Companies like 23andMe and Deep Genomics utilize AI to
analyze genetic markers and propose tailored therapies. Studies have shown that AI-based
personalization increases therapeutic efficacy by approximately 40%, especially in oncology
and rare diseases.
In manufacturing, AI ensures process automation, quality control, and predictive
maintenance. Pfizer’s AI-integrated facilities have reduced human errors by 90%. Moreover,
blockchain combined with AI is employed to combat counterfeit drugs by tracking
authenticity across the supply chain, as seen in the MediLedger project.
DISCUSSION
The pharmaceutical sector faces significant hurdles in managing high-quality,
standardized data. Approximately 72% of pharmaceutical companies report fragmented or
incomplete datasets, making it difficult to train reliable AI models. Solutions include federated
learning, which allows decentralized model training, and the use of synthetic data generated
by GANs. Adoption of FAIR (Findable, Accessible, Interoperable, Reusable) data principles is
also recommended to improve data usability across institutions.
EURASIAN JOURNAL OF MEDICAL AND
NATURAL SCIENCES
Innovative Academy Research Support Center
IF = 7.921
Volume 5 Issue 8, August 2025 ISSN 2181-287X
Page 30
As seen in the figure and table above, the pharmaceutical AI market has shown
consistent exponential growth over the last five years, driven by innovations in generative
modeling, clinical optimization tools, and real-world data integration.
Another pressing concern is data security. In 2023, nearly 45% of data breaches in
healthcare involved AI infrastructure. To mitigate risks, differential privacy and homomorphic
encryption are being implemented to protect sensitive patient data.
Growth of the AI Pharmaceutical Market (2019–2024)
Year
Market Size (USD Billion)
2019.0
1.2
2020.0
2.0
2021.0
3.1
2022.0
4.4
2023.0
5.5
2024.0
6.8
AI’s ‘black box’ nature, where decisions are made without clear interpretability, remains
problematic in healthcare. Studies show that 85% of clinical AI tools are non-explainable,
limiting trust and regulatory approval. Explainable AI (XAI) frameworks such as SHAP and
LIME help unpack model behavior and ensure transparency.
Algorithmic bias is another ethical issue. For instance, some dermatological AI systems
show a 35% lower accuracy for dark-skinned patients. Bias mitigation involves using diverse,
balanced training datasets and fairness-aware algorithms like FairML.
Regulatory fragmentation across jurisdictions complicates AI drug development. The
FDA issued an AI/ML Action Plan in 2023, while the EMA released a reflection paper in 2024.
However, ongoing model updates, lack of harmonized guidelines, and varied compliance
requirements hinder progress.
Classification of AI Applications in Pharma
EURASIAN JOURNAL OF MEDICAL AND
NATURAL SCIENCES
Innovative Academy Research Support Center
IF = 7.921
Volume 5 Issue 8, August 2025 ISSN 2181-287X
Page 31
Stage
AI Application
Example Tool/Company
Drug Discovery
Generative modeling
Insilico Medicine
Target Identification
Machine learning on
omics data
BenevolentAI
Clinical Trials
Patient recruitment
optimization
IBM Watson Health
Pharmacovigilance
Adverse event detection
FDA Sentinel,
MedWatcher
Personalized Medicine
Genomics-based therapy
design
Deep Genomics, 23andMe
Manufacturing
Process automation and
quality control
Pfizer AI Factory
Suggested solutions include creating global harmonization frameworks under the ICH
and adopting blockchain-based regulatory tracking systems for auditability and traceability.
Ethical dilemmas such as patient consent for data usage, accountability for AI-driven
decisions, and the digital divide are rising concerns. To address these, institutions should
establish clear ethical codes, provide AI literacy programs for patients, and introduce
algorithmic audits.
High implementation costs, a lack of skilled personnel, and insufficient computing
infrastructure impede AI deployment. The average cost to launch a pharmaceutical AI project
ranges between $1.2–1.8 million. Public-private partnerships, cloud-based AI tools, and open-
source frameworks can alleviate some of these constraints.
CONCLUSION
Artificial intelligence (AI) is rapidly transforming the pharmaceutical industry by
enabling faster, more cost-effective, and highly precise approaches to drug discovery,
development, and personalized patient care. This technological evolution not only accelerates
research timelines but also enhances diagnostic accuracy, optimizes clinical trials, and
improves therapeutic outcomes. The integration of AI-driven tools—such as machine learning
algorithms, predictive analytics, and natural language processing—into pharmaceutical
workflows is reshaping traditional paradigms and opening new frontiers in biomedical
innovation.
For emerging economies such as Uzbekistan, this presents a unique strategic
opportunity. By investing in digital infrastructure, fostering interdisciplinary education, and
establishing strong international research partnerships, Uzbekistan can position itself as a
regional hub for AI-powered pharmaceutical innovation. Building local expertise, encouraging
knowledge exchange, and implementing supportive regulatory frameworks will be essential
in cultivating a sustainable innovation ecosystem. If these foundational steps are taken,
Uzbekistan could play a leading role in shaping the future of healthcare not only regionally,
but also globally.
EURASIAN JOURNAL OF MEDICAL AND
NATURAL SCIENCES
Innovative Academy Research Support Center
IF = 7.921
Volume 5 Issue 8, August 2025 ISSN 2181-287X
Page 32
References:
1.
Zhavoronkov, A., et al. (2022). Deep learning enables rapid identification of potent DDR1
kinase inhibitors. Nature Biotechnology, 40(3), 123–135. https://doi.org/10.1038/s41587-
021-01013-3
2.
Topol, E. (2023). AI in Clinical Medicine: A Practical Guide. Wiley-Blackwell.
3.
Mak, K.K., & Pichika, M.R. (2023). Artificial intelligence in drug development. Drug
Discovery Today, 28(1), 103–115. https://doi.org/10.1016/j.drudis.2022.10.017
4.
FDA (2023). Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a
Medical Device Action Plan.
5.
EMA (2024). Reflection Paper on the Use of AI in the Medicinal Product Lifecycle.
https://www.ema.europa.eu
6.
McKinsey & Company (2023). Pharma 4.0: How AI is Transforming Drug Development.
7.
Deloitte (2024). Global AI in Pharma Market Forecast 2025–2030.
8.
NeurIPS
(2023).
Federated
Learning
for
Healthcare
Data
Privacy.
https://proceedings.neurips.cc
